Pseudomonas Aeruginosa Treatment Market Research Report - Forecast till 2027

Pseudomonas Aeruginosa Treatment Market Research Report: By Medication (Monotherapy, Combination Therapy), Route of Administration (Oral, Intravenous, Nasal) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Forecast to 2027

ID: MRFR/HC/6966-HCR | January 2023 | Region: Global | 105 Pages         

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Pseudomonas Aeruginosa Treatment Market, by Medication

1.1.2. Global Pseudomonas Aeruginosa Treatment Market, by Route of Administration

1.1.3. Global Pseudomonas Aeruginosa Treatment Market, by Distribution Channel

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.5. Breakdown of Primary Respondents

3.6. Forecasting Techniques

3.7. Research Methodology for Market Size Estimation

3.8. Bottom-Up Approach

3.9. Top-Down Approach

3.10. Data Triangulation

3.11. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porterโ€™s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.2.1. R&D and Designing

5.2.2. Manufacturing

5.2.3. Distribution & Sales

5.2.4. Post Sales Services

6. GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION

6.1. Overview

6.2. Monotherapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Combination Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

7.1. Overview

7.2. Nasal

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Oral

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Intravenous

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

8.1. Overview

8.2. Hospital Pharmacies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Retail Pharmacies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Online Pharmacies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitor Dashboard

10.3. Major Growth Strategy in the Global Pseudomonas Aeruginosa Treatment Market

10.4. Competitive Benchmarking

10.4.1. The Leading Player in terms of Number of Developments in the Global Pseudomonas Aeruginosa Treatment Market

10.5. Key Developments & Growth Strategies

10.6. Major Players Financial Matrix & Market Ratio

11. COMPANY PROFILES

11.1. Gilead Sciences Inc

11.1.1. Company Overview

11.1.2. Products/Services Offered

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Teva Pharmaceutical Industries Ltd.

11.3. Novartis AG

11.4. Pfizer, Inc.

11.5. Lupin Pharmaceuticals, Inc.

11.6. PARI Medical Holding GmbH

11.7. AstraZeneca

11.8. Humanigen Inc

11.9. Merck & Co., Inc.

11.10. AmpliPhi Biosciences Corp

11.11. Bristol-Myers Squibb Co.

11.12. Janssen Pharmaceuticals, Inc.

11.13. Bayer AG

11.14. Aradigm Corp

11.15. Allergan Plc

11.16. Others

12. APPENDIX

12.1. References

12.2. Related Reports

โ€ƒ

LIST OF TABLES

TABLE 1 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 10 US: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 11 US: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 12 US: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 13 CANADA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 14 CANADA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION)

TABLE 15 CANADA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY MEDICATION, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

โ€ƒ

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET

FIGURE 4 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE, BY MEDICATION, 2020 (%)

FIGURE 5 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE, BY ROUTE OF ADMINISTRATION 2020 (%)

FIGURE 6 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020 (%)

FIGURE 7 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 AMERICAS: PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL PSEUDOMONAS AERUGINOSA TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 GILEAD SCIENCES INC: KEY FINANCIALS

FIGURE 16 GILEAD SCIENCES INC: SEGMENTAL REVENUE

FIGURE 17 GILEAD SCIENCES INC: REGIONAL REVENUE

FIGURE 18 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY FINANCIALS

FIGURE 19 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SEGMENTAL REVENUE

FIGURE 20 TEVA PHARMACEUTICAL INDUSTRIES LTD.: REGIONAL REVENUE

FIGURE 21 NOVARTIS AG: KEY FINANCIALS

FIGURE 22 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 23 NOVARTIS AG: REGIONAL REVENUE

FIGURE 24 PFIZER, INC.: KEY FINANCIALS

FIGURE 25 PFIZER, INC.: SEGMENTAL REVENUE

FIGURE 26 PFIZER, INC.: REGIONAL REVENUE

FIGURE 27 LUPIN PHARMACEUTICALS, INC.: KEY FINANCIALS

FIGURE 28 LUPIN PHARMACEUTICALS, INC.: SEGMENTAL REVENUE

FIGURE 29 LUPIN PHARMACEUTICALS, INC.: REGIONAL REVENUE

FIGURE 30 PARI MEDICAL HOLDING GMBH: KEY FINANCIALS

FIGURE 31 PARI MEDICAL HOLDING GMBH: SEGMENTAL REVENUE

FIGURE 32 PARI MEDICAL HOLDING GMBH: REGIONAL REVENUE

FIGURE 33 ASTRAZENECA: KEY FINANCIALS

FIGURE 34 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 35 ASTRAZENECA: REGIONAL REVENUE

FIGURE 36 HUMANIGEN INC: KEY FINANCIALS

FIGURE 37 HUMANIGEN INC: SEGMENTAL REVENUE

FIGURE 38 HUMANIGEN INC: REGIONAL REVENUE

FIGURE 39 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 40 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 41 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 42 AMPLIPHI BIOSCIENCES CORP: KEY FINANCIALS

FIGURE 43 AMPLIPHI BIOSCIENCES CORP: SEGMENTAL REVENUE

FIGURE 44 AMPLIPHI BIOSCIENCES CORP: REGIONAL REVENUE

FIGURE 45 BRISTOL-MYERS SQUIBB CO.: KEY FINANCIALS

FIGURE 46 BRISTOL-MYERS SQUIBB CO.: SEGMENTAL REVENUE

FIGURE 47 BRISTOL-MYERS SQUIBB CO.: REGIONAL REVENUE

FIGURE 48 JANSSEN PHARMACEUTICALS, INC.: KEY FINANCIALS

FIGURE 49 JANSSEN PHARMACEUTICALS, INC.: SEGMENTAL REVENUE

FIGURE 50 JANSSEN PHARMACEUTICALS, INC.: REGIONAL REVENUE

FIGURE 51 BAYER AG: KEY FINANCIALS

FIGURE 52 BAYER AG: SEGMENTAL REVENUE

FIGURE 53 BAYER AG: REGIONAL REVENUE

FIGURE 54 ARADIGM CORP: KEY FINANCIALS

FIGURE 55 ARADIGM CORP: SEGMENTAL REVENUE

FIGURE 56 ARADIGM CORP: REGIONAL REVENUE

FIGURE 57 ALLERGAN PLC: KEY FINANCIALS

FIGURE 58 ALLERGAN PLC: SEGMENTAL REVENUE

FIGURE 59 ALLERGAN PLC: REGIONAL REVENUE